Literature DB >> 23588157

The role of purinergic pathways in the pathophysiology of gut diseases: pharmacological modulation and potential therapeutic applications.

Luca Antonioli1, Rocchina Colucci, Carolina Pellegrini, Giulio Giustarini, Marco Tuccori, Corrado Blandizzi, Matteo Fornai.   

Abstract

Gut homeostasis results from complex neuro-immune interactions aimed at triggering stereotypical and specific programs of coordinated mucosal secretion and powerful motor propulsion. A prominent role in the regulation of this highly integrated network, comprising a variety of immune/inflammatory cells and the enteric nervous system, is played by purinergic mediators. The cells of the digestive tract are literally plunged into a "biological sea" of functionally active nucleotides and nucleosides, which carry out the critical task of driving regulatory interventions on cellular functions through the activation of P1 and P2 receptors. Intensive research efforts are being made to achieve an integrated view of the purinergic system, since it is emerging that the various components of purinergic pathways (i.e., enzymes, transporters, mediators and receptors) are mutually linked entities, deputed to finely modulating the magnitude and the duration of purinergic signaling, and that alterations occurring in this balanced network could be intimately involved in the pathophysiology of several gut disorders. This review article intends to provide a critical appraisal of current knowledge on the purinergic system role in the regulation of gastrointestinal functions, considering these pathways as a whole integrated network, which is capable of finely controlling the levels of bioactive nucleotides and nucleosides in the biophase of their respective receptors. Special attention is paid to the mechanisms through which alterations in the various compartments of the purinergic system could contribute to the pathophysiology of gut disorders, and to the possibility of counteracting such dysfunctions by means of pharmacological interventions on purinergic molecular targets.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23588157     DOI: 10.1016/j.pharmthera.2013.04.002

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  28 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

Review 2.  P2X4 receptors, immunity, and sepsis.

Authors:  Luca Antonioli; Corrado Blandizzi; Matteo Fornai; Pál Pacher; H Thomas Lee; György Haskó
Journal:  Curr Opin Pharmacol       Date:  2019-03-25       Impact factor: 5.547

3.  The ecto-enzymes CD73 and adenosine deaminase modulate 5'-AMP-derived adenosine in myofibroblasts of the rat small intestine.

Authors:  Anna Bin; Valentina Caputi; Michela Bistoletti; Monica Montopoli; Rocchina Colucci; Luca Antonioli; Sara De Martin; Ignazio Castagliuolo; Genny Orso; Cristina Giaroni; Patrizia Debetto; Maria Cecilia Giron
Journal:  Purinergic Signal       Date:  2018-09-29       Impact factor: 3.765

Review 4.  Purinergic drug targets for gastrointestinal disorders.

Authors:  Geoffrey Burnstock; Kenneth A Jacobson; Fievos L Christofi
Journal:  Curr Opin Pharmacol       Date:  2017-11-14       Impact factor: 5.547

Review 5.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 6.  Adenosine signalling in diabetes mellitus--pathophysiology and therapeutic considerations.

Authors:  Luca Antonioli; Corrado Blandizzi; Balázs Csóka; Pál Pacher; György Haskó
Journal:  Nat Rev Endocrinol       Date:  2015-02-17       Impact factor: 43.330

7.  Connexin-purinergic signaling in enteric glia mediates the prolonged effect of morphine on constipation.

Authors:  Sukhada Bhave; Aravind Gade; Minho Kang; Kurt F Hauser; William L Dewey; Hamid I Akbarali
Journal:  FASEB J       Date:  2017-03-09       Impact factor: 5.191

8.  P2X₇ receptor of rat dorsal root ganglia is involved in the effect of moxibustion on visceral hyperalgesia.

Authors:  Shuangmei Liu; Qingming Shi; Qicheng Zhu; Ting Zou; Guilin Li; An Huang; Bing Wu; Lichao Peng; Miaomiao Song; Qin Wu; Qiuyu Xie; Weijian Lin; Wei Xie; Shiyao Wen; Zhedong Zhang; Qiulan Lv; Lifang Zou; Xi Zhang; Mofeng Ying; Guodong Li; Shangdong Liang
Journal:  Purinergic Signal       Date:  2014-12-20       Impact factor: 3.765

9.  Optogenetic analysis of neuromuscular transmission in the colon of ChAT-ChR2-YFP BAC transgenic mice.

Authors:  Alberto L Perez-Medina; James J Galligan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-14       Impact factor: 4.052

10.  Role of the A(2B) receptor-adenosine deaminase complex in colonic dysmotility associated with bowel inflammation in rats.

Authors:  L Antonioli; M Fornai; O Awwad; G Giustarini; C Pellegrini; M Tuccori; V Caputi; M Qesari; I Castagliuolo; P Brun; M C Giron; C Scarpignato; C Blandizzi; R Colucci
Journal:  Br J Pharmacol       Date:  2014-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.